Diabetes, obesity & metabolism · 2026
Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Hyung Seok John, Tran Tien Hoang, Schmickl Christopher N, Slejko Julia F
Аннотация
AIMS: To quantify the incremental economic and utilization burden of comorbid obstructive sleep apnea (OSA) within an overweight to severely obese adult population.
MATERIAL AND METHODS: This retrospective cohort study utilized 2016-2025 IQVIA PharMetrics Plus Closed Health Plan commercial claims data to identify overweight to severely obese adults aged 18-64 years. Patients with diagnosed OSA were propensity-score matched 1:1 to non-OSA controls. Generalized linear models were constructed to quantify the incremental burden of OSA through adjusted cost/rate ratios and average marginal effects (AMEs) over a 365-day follow up period. Outcomes were also stratified by obesity severity, cardiovascular disease (CVD), diabetes, sex, and baseline glucagon-like peptide-1 receptor agonist (GLP-1 RA) use.
RESULTS: Among OSA patients, 13 971 (99.9%) were successfully matched (total n = 27 942). Patients with OSA incurred significantly higher total healthcare costs compared to controls (adjusted cost ratio = 1.24; 95% CI = [1.20, 1.28]), corresponding to an AME of $6942 per patient. Costs were driven by routine disease management such as outpatient visits (AME = $2955) and prescription costs (AME = $3198). Subgroup analyses revealed that incremental costs were high among patients with CVD (AME = $9257) and notably, the incremental cost of OSA remained substantial even among chronic users of GLP-1 RAs (AME = $12359).
CONCLUSION: Comorbid OSA is associated with a significant increase in total healthcare costs driven largely by outpatient and prescription costs. This burden was concentrated among patients with cardiovascular comorbidity and persisted among chronic GLP-1 RA users.
MATERIAL AND METHODS: This retrospective cohort study utilized 2016-2025 IQVIA PharMetrics Plus Closed Health Plan commercial claims data to identify overweight to severely obese adults aged 18-64 years. Patients with diagnosed OSA were propensity-score matched 1:1 to non-OSA controls. Generalized linear models were constructed to quantify the incremental burden of OSA through adjusted cost/rate ratios and average marginal effects (AMEs) over a 365-day follow up period. Outcomes were also stratified by obesity severity, cardiovascular disease (CVD), diabetes, sex, and baseline glucagon-like peptide-1 receptor agonist (GLP-1 RA) use.
RESULTS: Among OSA patients, 13 971 (99.9%) were successfully matched (total n = 27 942). Patients with OSA incurred significantly higher total healthcare costs compared to controls (adjusted cost ratio = 1.24; 95% CI = [1.20, 1.28]), corresponding to an AME of $6942 per patient. Costs were driven by routine disease management such as outpatient visits (AME = $2955) and prescription costs (AME = $3198). Subgroup analyses revealed that incremental costs were high among patients with CVD (AME = $9257) and notably, the incremental cost of OSA remained substantial even among chronic users of GLP-1 RAs (AME = $12359).
CONCLUSION: Comorbid OSA is associated with a significant increase in total healthcare costs driven largely by outpatient and prescription costs. This burden was concentrated among patients with cardiovascular comorbidity and persisted among chronic GLP-1 RA users.